Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”) an innovative biotechnology company focused on developing ...
Panelists discuss how clinicians manage suboptimal responders by focusing on stability rather than complete dryness, using ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, ...
A 29-year-old woman was referred to Tufts Medical Center for undifferentiated bilateral anterior and intermediate uveitis.The ...
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as ...
FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...
Regeneron shares are up 41% in six months as FDA approvals, strong Dupixent profits and oncology gains lift investor confidence.
Regeneron stock lagged behind the S&P 500 last year. Why this firm moved off the sidelines. Regeneron Pharmaceuticals stock ...
Zacks Investment Research on MSN
OTLK stock crashes 67% in a week: Here's what you need to know
Shares of Outlook Therapeutics OTLK have tumbled 66.5% in a week. The massive crash was observed after the FDA issued a third ...
The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar in the U.S. from Formycon and Bioeq, the companies announced in a press ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback